Pfizer Q1 revenue falls 29% to $18.3B; adjusted EPS $1.23; reaffirms FY2023 guidance

PFIZER INC

2023-Q1 EPS reported $0.97 revenue$18,282,000,000

First-quarter 2023 revenues $18.3B (down 29% YoY); reported diluted EPS $0.97, adjusted diluted EPS $1.23 (down 24% YoY).
Comirnaty revenues dropped 75% operationally; Paxlovid revenues increased by $2.8B; ex-COVID products grew 5% operationally.
FY2023 guidance reaffirmed: revenue $67-71B, adjusted EPS $3.25-3.45; midpoint implies ~31% operational revenue decline.
Proposed acquisition of Seagen (oncology ADC) expected to close late 2023 or early 2024; integration planning underway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PFIZER INC reported first quarter of 2023 results: revenue $18,282 million, net income $5,543 million, EPS $0.97 per diluted share. Guidance reaffirmed.

Period: first quarter of 2023
Revenue: $18,282 million
Net income: $5,543 million
EPS: $0.97 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports First-Quarter 2023 Results ▪ First-Quarter 2023 Revenues of $18.3 Billion – Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues – First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1

View on SEC.gov

Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0001628280-23-014759

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.